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ABSTRACT Atherosclerosis is a major cause of morbidity
and mortality in developed countries. In humans the risk of
atherosclerosis is inversely correlated with plasma levels ofhig
density lipoprotein (HDL). As a step in determining whether
the experimental reduction of plasma HDL level will increase
susceplbility to atherosclerosis, we have used gene targeting in
embryonic stem cells to produce mice lacking apolipoprotein
A-I, the major protein component of HDL particles. Mice
homozygous for the disrupted gene have no plasma apolipo-
protein A-I detectable by double imunodifusion; their total
plasms cholesterol and FIDL-cholesterol levels aftr overnight
fang are reduced to about one-third and one-fifth of normal
levels, and they are grossly deficient in a-m ating IHDL
particles.
Inactivation of a specific gene in the genome of mouse
embryonic stem (ES) cells by homologous recombination
(gene targeting) followed by the generation of animals car-
rying the mutated gene is providing an increasing store of
biological insights (1, 2). The relevant technology has assisted
the understanding of the developmental roles played by
genes, such as oncogenes (3-5) and homeobox genes (6), and
knowledge about the immunological importance of mole-
cules, such as f32-microglobulin (7, 8) and interleukin4 (9),
has been greatly enhanced. Animals carrying a specific
single-gene defect in an otherwise normal genetic background
are, therefore, expected to be useful for studying the role of
the defect in the etiology of human genetic disease. Rela-
tionships between genotypes and phenotypes are generally
direct when the disease is caused by a single-gene defect, as
is exemplified by the hemoglobinopathies. However, when
more than one gene is involved and particularly when envi-
ronmental factors play an important role, the relationships
between genotypes and phenotypes become much more
complex. Examples include diabetes, hypertension, and ath-
erosclerosis. Gene-targeting experiments can, nevertheless,
provide another approach to unraveling the complex etiology
of such multifactorial diseases. Individual candidate genes
can be modified, and their isolated effects in the living animal
can be determined in controlled environments. Even more
powerfully, single-gene modifications can be combined by
breeding, so that eventually the genetics of the multifactorial
disease can be deciphered.
The present experiment, generation of mice carrying an
inactivated apolipoprotein A-I gene (Apoa-i), is a step to-
ward dissecting the role of genetic factors involved in lipid
metabolism and atherogenesis. Apolipoprotein A-I (apoA-I),
synthesized in the liver and small intestine, is the major
protein complexed with high density lipoprotein (HDL) in
mammals (10). In addition to its role in lipoprotein metabo-
lism as a structural protein, apoA-I'also participates in
cholesterol ester formation by serving as a cofactor for
lecithin-cholesterol acyltransferase (11). In humans an in-
verse correlation between the risk of developing atheroscle-
rosis and plasma levels of HDL has been observed (12).
Human individuals deficient in apoA-I caused by several
different types of mutation in the gene appear to be predis-
posed to atherosclerosis (13-18). These observations point to
the importance of apoA-I and HDL particles in atherogene-
SIS.
The negative correlation between HDL levels and athero-
sclerosis observed in humans is supported by differences in
susceptibility to dietary-induced atherosclerosis in mice of
different strains. Thus C57BL/6 mice are more susceptible
than are C3H or BALB/c mice (19), and this susceptibility
segregates with a genetic determinant, Ath-i, that appears to
control the plasma level of HDL in response to high fat diet
(20). Furthermore, C57BL/6 mice show a 2-fold lower HDL-
cholesterol level after being fed an atherogenic diet than do
mice of the other two strains. Finally, evidence that apoA-I
expression is a major determinant of atherosclerosis comes
from the protective effects against high dietary lipids afforded
by over-production ofhuman apoA-I in transgenic mice (21);
this leads to as much as 3-fold higher levels of total and HDL
cholesterol (21, 22). As a first step to examine the effects of
absence of apoA-I on atherogenesis in mice, we have con-
structed mice having their Apoa-1 gene inactivated by gene
targeting. Here we report these experiments, which have
produced mice lacking in plasma apoA-I and grossly deficient
in their plasma HDL levels.
MATERIALS AND METHODS
Cloning of the Mouse Apoa-1 Locus and Construction of the
Targeting Plasmid. A 9-kilobase (kb) BamlII fragment of
mouse genomic DNA containing the Apoa-i gene and a part
ofthe gene for apolipoprotein C-III was isolated by screening
a A phage library made from DNA of a strain 129/Ola mouse.
We determined the nucleotide sequence of %5 kb of the
fragment to establish its validity; the sequence is 89%o
identical to the equivalent region of the rat sequence (23). A
targeting construct designed to disrupt the endogenous
Apoa-i locus after the homologous recombination was made
by replacing the 400-base-pair (bp) EcoRV-EcoRI fragment
containing exon 2 of the gene with the positively selectable
neomycin resistance gene (pMClneopolyA, Stratagene). A
herpes simplex virus thymidine kinase (TK) gene was placed
either at the 5' or 3' end of the construct to make 5'TK or
3'TK constructs, respectively.
Gene Targeting and Screening of the Ho g Recbi-
nants. ES cell (E14TG2a) culture and electroporations were
Abbreviations: apoA-I, apolipoprotein A-I; ES cells, embryonic
stem cells; HDL, high density lipoproteins; TK, thymidine kinase.
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done as described (24, 25). Before electroporation, the target-
ing plasmids were linearized at a Not I site in the vector. Ten
to twelve days after electroporation, colonies resistant to G418
(200 jig/ml, Sigma) and to 2 A&M ganciclovir (from Syntex, Palo
Alto, CA) were picked and passaged in clonal fashion. DNA
was isolated for Southern analysis from 60-mm dishes of
nearly confluent ES cells by standard methods or from 20-mm
dishes by a salting-out method (26). Three micrograms ofDNA
was digested with restriction enzymes, and Southern blots
were made using conventional procedures.
Generation of Germ-Line-Competent Chimeras. Approxi-
mately 10 ES cells were injected into the blastocoele cavity
of C57BL/6J embryos. Surviving blastocysts were trans-
ferred to the uteri of pseudopregnant CD-1 or C57BL x CBA
F1 females. An average of two to three transfers were made
per cell line. Animals chimeric by coat color were bred to
C57BL/6J animals to determine their germ-line competency.
Measuring Total and HDL Cholesterol. Total plasma cho-
lesterol levels were measured enzymatically by using 1 or 2
Al of plasma and 100 pl of commercially available reagents
(Sigma). HDL-cholesterol levels were measured after remov-
ing apolipoprotein B-containing particles by precipitation
with polyethylene glycol (21). Measurements were made in
duplicate and averaged for samples collected from 8-week-
old homozygotes and heterozygotes derived from two F1
heterozygote matings. Values for seven normal animals of
approximately the same age but from other F1 x F1 matings
are given for comparison. Before fasting overnight, the
animals had been on breeding chow (ProLab 2000 formula),
which contains -9% crude fat.
RESULTS
Targeting constructs were made by using a 9-kb BamHI
fragment isolated from strain 129 mouse genomic DNA that





region sequences (including part of the gene for apolipopro-
tein C-III). Exon 2 of the Apoa-l gene in the fragment was
replaced by sequences from pMClneopolA (27) that confer
resistance to G418 in mammalian cells. These sequences are
in the same transcriptional orientation as the Apoa-l gene. A
herpes simplex virus TK gene was placed either at the 5'TK
or at the 3'TK of the construct to allow use of a positive/
negative-selection strategy with G418 and ganciclovir (28).
Fig. 1 illustrates the scheme ofhomologous recombination by
using the 5'TK construct and shows the positions of probes
used in analysis of the experimental data.
The targeting DNA was introduced into ES cells
(E14TG2a) (29) by electroporation, and DNA samples from
ES cell colonies resistant to G418 and ganciclovir were
assayed for targeting by Southern blotting (Fig. 2). Probe 1
hybridizes to a single 12.0-kb HindIII fragment in DNA from
parental cells (lane 6 of Fig. 2a) but hybridizes to this
fragment and to an additional 4.6-kb fragment of equal
intensity in DNA from targeted cells (lanes 2-5 in Fig. 2a).
DNA from cells that have incorporated the targeting DNA
elsewhere in the genome, by a nonhomologous event, give
HindIII fragments of unpredictable sizes, as exemplified by
lane 1 in Fig. 2a. Targeting was confirmed by the presence, of
an 8.5-kb HindIII fragment after hybridization to probe 2,
probe 3, or to a probe specific for the neo gene (data not
shown), and by Southern blots of digests with other restric-
tion enzymes. For example, Fig. 2b shows additional Nhe I
and Bcl I fragments of the expected sizes in DNA from two
of the targeted cells in addition to fragments of the same size
as those from parental cells; hybridization was to probe 1.
Table 1 summarizes the targeting data from five experi-
ments, the first two with the 5'TK construct and the remain-
ing three with the 3'TK construct. As the data show, the
frequency oftargeting the mouse Apoa-J locus was very high,
ranging from 82% (experiment 1) of colonies that survived
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FIG. 1. Strategy for targeting the mouse Apoa-l gene. (Top) EndogenousApoa-l and ApoCIJI loci, each with four exons that are convergently
transcribed. (Middle) Targeting construct. The construct contains a HindIII and a Bcl I site at the 3' end of the neo gene that are not present
in the native locus. (Bottom) A correctly targeted locus depicted after a homologous crossover. Restriction fragment lengths of parental and
modified loci used to identify the correct modification are indicated. Probes 1, 2, and 3 are a 2-kb BamHI-Xba I fragment, a 1-kb EcoRI fragment,
and a 600-bp Kpn I-BamHI fragment, respectively. B, BamHI; Bc, Bcl I; H, HindIII; N, Not I; Nh, Nhe I; and R, EcoRI.
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FIG. 2. Southern blot analysis ofDNA from ES cell colonies. (a)
Southern blot of genomic DNA from six ES cell colonies digested
with HindIll and hybridized to probe 1 (Fig. 1). Parental cell DNA
is in lane 6; the 12-kb band is from the unmodified Apoa-1 gene.
Lanes 2-5 contain DNA from colonies that have been correctly
targeted; a 4.6-kb band is present in addition to the 12-kb band. Lane
1 is DNAfrom a colony in which the targeting DNA was incorporated
into the genome somewhere else, giving a band ofunpredictable size,
while leaving the 12-kb parental band intact. (b) The planned
modification was confirmed by Southern blot analysis of DNA
digested with other restriction enzymes. The blot was hybridized
with probe 1. Lane 1 is DNA from parental cells digested with Nhe
I; lanes 2 and 3 are DNA from targeted colonies digested with Nhe
I; lane 4 is DNA from parental cells digested with Bcl I; lanes 5 and
6 are DNA from targeted colonies digested with Bcl I.
(experiment 5) with the 3'TK construct. Homologous recom-
bination occurred under our conditions approximately once
per 105 treated cells. Ganciclovir selection gave a 2- to 4-fold
enrichment over that seen with G418 alone, as demonstrated
in experiment 3, in which 19% (8/42) of G418-resistant cells
were targeted.
When injected into blastocysts, the targeted cell lines
varied in the extent of chimerism produced in resulting
offsprings. Two out of nine lines used for injection were
germ-line competent: one of them gave three male chimeras
able to transmit the ES cell genome to their offspring; another
gave one germ-line-competent female chimera. Southern blot
analysis of DNA isolated from the tails of ES cell-derived
offspring of a male chimera mated to C57BL/6J females
showed that %50%o of them inherited the inactivated Apoa-l
allele.
Animals homozygous for the modified Apoa-1 gene were
generated from matings of heterozygotes. Southern blot
analysis ofDNA isolated from the tails of nine pups from two
litters is shown in Fig. 3a. In four of these samples (pup
numbers 27-29 and 32), probe 3 (see Fig. 1) hybridized to a
single 8.5-kb HindIII fragment; this result establishes that
these animals are homozygous for the modified Apoa-1 gene.
Pups 30, 31, 34, and 35 were heterozygotes (8.5-kb and 12-kb
bands), and number 33 had no modified genes (12-kb band
only). Animals homozygous for the disrupted Apoa-J appear
healthy at their present age (2-3 mo).
Mice homozygous for the disrupted Apoa-1 gene have no
apoA-I in their plasma detectable by Ouchterlony double-
immunodiffusion tests against rabbit anti-mouse apoA-I an-
tiserum (Fig. 3b), although strong precipitation is clearly
visible with plasma from animals heterozygous or homozy-
gous for the normal gene. This result establishes that at the
protein level the planned modification eliminated apoA-I
production, as was expected from the design of the targeting
construct.
At the lipid level, we find (Table 2) that the total cholesterol
in plasma from homozygous mutants at 8 weeks of age is
=33% that of normal animals of similar age (P < 0.0005).
HDL-cholesterol levels in the animals show an even greater
reduction (17%, P < 0.0005). Heterozygous animals have
total cholesterol and HDL-cholesterol levels 54% and 40o,
respectively, of the levels in normal animals.
Electrophoresis ofplasma samples on nondenaturing poly-
acrylamide gradient gels (Fig. 3c) shows that the homozygous
animals (animals 27-29 and 32) are grossly deficient in HDL
particles. There is also an overall reduction of the HDL
particles in heterozygotes (animals 30, 31, and 34) in com-
parison with normal (animal 33), but the size distribution of
particles in heterozygotes is not markedly altered.
DISCUSSION
We have used gene targeting to produce mice lacking apoA-I.
The overall efficiency of targeting the Apoa-1 gene in mouse
ES cells was one in 10W of the treated cells. About one-fifth
of ES cell colonies surviving a single positive selection and
about one-half of surviving double-positive-negative selec-
tion were correctly targeted. We used isogenic DNA as a
source of targeting DNA and used =2.5 kb and 6 kb of
genomic sequences at each side of the neo gene to facilitate
the homologous recombination. Targeting frequencies simi-
lar to those we report here have been demonstrated for the
pim-l protooncogene (30) but can be orders of magnitude
less. With the same ES cells, similar lengths of sequence
homology, and essentially identical experimental conditions,
the frequencies of obtaining targeted cells has varied, in our
own and our colleagues' hands, from one in 10W treated cells
for the Apoa-1 gene (this paper), one in 106 for the hypoxan-
thine phosphoribosyltransferase gene (31) and the apolipo-
protein E (Apoe) gene (24) and less than one in 107 in the
cystic fibrosis transmembrane regulator gene (B. Koller,
personal communication). All the targeting constructs used in
these experiments were isogenic, except for that with the
Apoe gene. It is not understood at this point what makes one
locus more accessible to homologous recombination than
another; it may be a property of the locus and/or of the
sequence in the incoming DNA. Experiments dissecting the
Apoa-l gene region with a view to identifying elements that
influence the frequency ofhomologous recombination events
would be worthwhile.
Animals homozygous for the inactivated Apoa-l gene
appear healthy at age 3 mo, although they lack apoA-I protein
in their plasma and have only one-fifth of HDL cholesterol
compared with normal. Heterozygotes also have their HDL-
cholesterol levels reduced (to 40%). That the mutant animals
appear healthy is very important. This fact proves that
apoA-I is not vital to the normal development of mice,
confirming the deduction one would make from the existence
Table 1. Homologous recombination of the mouse Apoa-1 gene
Colonies Targeted
DNA Cells Colonies analyzed, colonies,
Exp. (conc.) treated Selection surviving, no. no. no. (%)
1 5'TK (5 nM) 4 X 107 G418 + Ganciclovir 150 28 24 (82)
2 5'TK (2 nM) 3 x 107 G418 + Ganciclovir 2500 50 35 (70)
3 3'TK (2 nM) 2.5 x 107 G418 1253 42 8 (19)
4 3'TK (2 nM) 5.8 x 107 G418 + Ganciclovir 1240 47 29 (62)
5 3'TK (2 nM) 2.9 X 107 G418 + Ganciclovir 851 48 20 (46)
Exp., experiment; conc., concentration.
a
1 2 3 4 5 6
-12 kb
4.6
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FIG. 3. (a) Southern blot analysis of tail DNA. DNA samples
were isolated from the tails of 3-week-old animals resulting from two
heterozygote matings. Probe 3 (Fig. 1) was used to identify the 8.5-kb
HindIII band diagnostic of the modified Apoa-1 gene. Animals 27-29
and 32 are homozygous for the mutation (-/-); animals 30, 31, 34,
and 35 are heterozygous (+/-); animal 33 is homozygous normal
(+/+). (b) Ouchterlony double-immunodiffusion precipitation of
plasma from nine pups (animals 27-35) from heterozygote F1 matings
and from three control mice (C1-C3). Plasma (0.2 pd) was diluted
with phosphate-buffered saline and placed in the peripheral wells
made in 1.0% agarose/phosphate-buffered saline/3% polyethylene
glycol (PEG 8000) (24); 5 ,u of antiserum was in the central well.
-/-, +/-, and +/+ indicate samples, respectively, from homozy-
gous mutants, heterozygous mutants, and nonmutant animals. (c)
Native gel electrophoresis of plasma. Plasma samples (15 1d) were
collected after overnight fasting from the same animals at 8 weeks of
age as were used for the Ouchterlony test and were prestained with
Sudan black. Electrophoresis was done in a 4-20%6 gradient poly-
acrylamide gel (Bio-Rad) by using Tris/glycine buffer at pH 8.3.
of humans who lack apoA-I. Survival of apoA-I-deficient
animals will enable detailed studies of the consequences in
mice of apoA-I deficiencies in lipid metabolism and athero-
genesis. In humans lacking apoA-I, a marked reduction of
HDL cholesterol has been observed. Changes in the total
cholesterol in these individuals (-67%; ref. 32) are, however,
not so obvious as in our mutant mice (33% in homozygotes
and 54% in heterozygotes). This difference may be a conse-
quence of the fact that the major cholesterol carrier in mice
is HDL, whereas in humans it is low density lipoprotein (ref.
Table 2. Cholesterol levels in plasma of animals carrying mutant
Apoa-1 genes
Genotype Total cholesterol, mean HDL cholesterol, mean
(n) mg/dl ± SD mg/dl ± SD
Homozygote
(4) 28.7 ± 8.6 (P < 0.0005)* 13.2 ± 4.6 (P < 0.0005)
Heterozygote
(3) 47.5 ± 9.2 (P < 0.05) 30.3 ± 13.5 (P < 0.01)
Control (7) 88.3 ± 18.0 75.6 ± 16.2
*P values are against controls.
33). However, the two species are similar in that the lack of
apoA-I does not appear to affect the amount of lipoprotein
particles other than HDL. Humans lacking apoA-I suffer
from premature coronary heart diseases. It will, therefore, be
of great interest to determine whether the homozygous or
even heterozygous mutants having reduced levels of plasma
HDL develop atherosclerosis spontaneously as they age, as
well as to investigate how they respond to atherogenic diets.
No strains of mice are known that develop atherosclerosis
spontaneously when fed standard chow (:5% in fat). A
high-fat diet (-15%) induces fat accumulations in the aorta of
some strains of mice that are equivalent to early lesions seen
in human atherosclerosis. We anticipate that the inactivated
Apoa-1 gene will have different effects in different genetic
backgrounds.
It will be of interest to backcross the apoA-I-deficient F1
heterozygotes to normal C57BL/6J animals so that the ef-
fects of the mutation can be studied in the C57BL/6J back-
ground, which is associated with susceptibility to dietary-
induced atherosclerosis. It will also be important to study the
effects of the mutation in the moderately resistant 129 back-
ground by mating chimeras and their offspring solely to strain
129 animals. Furthermore, studying mice carrying the null
Apoa-1 allele together with a null apolipoprotein E (Apoe)
allele (24) should be of great interest. Apolipoprotein E-de-
ficient mice are expected to have elevated levels of plasma
cholesterol as a result of a reduced ability to clear chylomi-
cron remnants and very low density lipoprotein remnants.
The combination of these two defects, both potentially
atherogenic, should, therefore, increase the likelihood that
animals will be obtained that develop atherosclerosis spon-
taneously, even when fed a normal diet.
In conclusion, we have used homologous recombination in
ES cells to generate mice carrying a disrupted Apoa-1 gene.
These mice should be of great use in dissecting the role of
apoA-I in lipid metabolism. Study of the effects of our
inactivated Apoa-1 gene mutation in different normal genetic
backgrounds and in combination with other potentially
atherogenic mutations should allow better understanding of
the complex process of atherogenesis. Such animals should
be valuable models for the development of additional drugs
and therapies for reducing the incidence of coronary heart
disease.
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